AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05430295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monofocal intraocular lens implantation
Description: implantation of monofocal intraocular lens in the capsular bag at the end of phacoemulsification surgery
Study NCT05340127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEREBO®
Description: Usability Study
Study NCT05911997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTC 01
Description: Slurry to be administered via colonoscopy
Study NCT05911997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
Study NCT05911997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
Study NCT04738539 — intervention group
Intervention type: DRUG
Intervention: Contrast Enhanced Voiding Urosonography with Urodynamic Testing
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
Study NCT04738539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic Testing
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
Study NCT05361330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuganjieyu capsule
Description: 2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
Study NCT05361330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
Study NCT05361330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
Study NCT06626776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral sinus lift with using allograft and collagen membrane
Description: sinus floor elevation with placing allograft and collagen membrane
Study NCT06626776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral sinus lift with using exteneded platelet rich fibrin
Description: sinus floor elevation with placing eprf
Study NCT05886023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High nitrate vegetables
Description: Vegetable burger containing high nitrate vegetables
Study NCT05886023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low nitrate vegetables
Description: Vegetable burger containing to low nitrate vegetables
Study NCT06401512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) follow-up approach by primary care nurses.
Description: The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
Study NCT05831202 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The SEAL™ Saccular Endovascular Aneurysm Lattice System
Description: All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.
Study NCT06075901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Flossing
Description: Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.
Study NCT06075901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Cuff
Description: Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
Study NCT06075901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training Protocol
Description: The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
Study NCT06075901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Protocol
Description: The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.
Study NCT06485531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pranamaya
Description: Pranamaya
Study NCT06485531 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pursed Lips Breathing
Description: Pursed Lips Breathing
Study NCT05313230 — intervention group
Intervention type: OTHER
Intervention: CITRASATE SLED
Description: Applying of CITRASATE SLED
Study NCT04641286 — intervention group
Intervention type: OTHER
Intervention: Body motion categorisation
Description: All patients will receive passive motion categorisation monitoring
Study NCT05361512 — intervention group
Intervention type: DEVICE
Intervention: Tsui test
Description: The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
Study NCT05361512 — intervention group
Intervention type: DEVICE
Intervention: epidural waveform analysis
Description: A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
Study NCT05276219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Study NCT05276219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
Study NCT05276219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide and isosorbide dinitrate
Description: Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
Study NCT05373173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-assessment + In-person assessment
Description: All consented families will complete an initial home-based tele-assessment visit via Zoom that includes the TAP-Preschool and a brief symptom-focused developmental interview with a consented clinician. The initial tele-assessment session includes interviewing and developmental assessment to mimic real-world use of TAP-Preschool. After the session, the examiner will record the clinical diagnosis issued (ASD, other developmental concerns, or typical development) and complete two diagnostic certainty ratings. All initial TAP-Preschool administrations will be recorded via Zoom, and 50% of administrations (randomly selected) will be co-scored by a blinded examiner, unaware of prior assessment results and diagnostic decision, to evaluate inter-rater reliability. Within 7 days of the remote assessment, families will participate in an in-person diagnostic assessment including common comprehensive measures of ASD, cognitive skills, and adaptive behavior.
Study NCT06742632 — intervention group
Intervention type: BEHAVIORAL
Intervention: Symptoms checklist-90
Description: The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.
Study NCT06741592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDDY Group
Description: The EDDY activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
Study NCT06741592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUI Group
Description: The passive ultrasonic activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
Study NCT06741462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital health assistant ADELE A0004
Description: The digital health assistant ADELE A0004 (ADELE for short) improves the daily lives of patients with care level and enables them to deal better and more independently with the everyday burdens resulting from the need for care. Participants in the intervention group were provided with ADELE to use during the study period for e.g., tracking of daily reminders, voice-based recording, interpretation and classification of their vital signs and body conditions.
Study NCT06742021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Description: Chest MRI scans outside of the standard treatment protocol
Study NCT06030752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study NCT05979116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release
Description: MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
Study NCT05816785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
Study NCT05816785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 400 mg orally daily
Study NCT05655078 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Description: 5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
Study NCT06432647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1105
Description: ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
Study NCT06432647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
Study NCT06413433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Description: Solriamfetol tablets, taken once daily
Study NCT06413433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Description: Solriamfetol tablets, taken once daily
Study NCT06413433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken once daily
Study NCT05051930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
Study NCT05051930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 suspension placebo for inhalation
Description: Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .
Study NCT05866848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flour capsules as a placebo.
Study NCT05866848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (45mg)
Description: Capsules dosed with 45mg of anhydrous caffeine.
Study NCT05866848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anhydrous caffeine (120mg)
Description: Capsules dosed with 120mg of anhydrous caffeine.
Study NCT05086237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
Study NCT05200767 — intervention group
Intervention type: OTHER
Intervention: completing surveys
Description: The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results.
Study NCT04769362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinuation of β-blocker
Description: Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction
Study NCT05232526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mental imagery (MI) and exercise program
Description: Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
Study NCT05232526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental imagery (MI) and exercise program
Description: Mental imagery and exercise program will be used to improve balance, functional status, cognitive ability, depression and quality of life of the sample
Study NCT05232526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mental Imagery and Exercise program
Description: Questionnaires and functional tests are going to be used to evaluate balance, functional status, cognitive ability, depression and quality of life of the sample.
Study NCT05916248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen tumor vaccine
Description: Neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
Study NCT04261738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen
Description: Volunteers will be given a standard hyperbaric oxygen treatment (2.4 ATA x 90 minutes)
Study NCT05591833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SASI
Description: Single-Anastomosis Sleeve ileal (SASI) Bypass
Study NCT05591833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAS-J
Description: Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
Study NCT04772235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Repotrectinib will be taken orally once daily with or without food Part A: Dose escalation phase, with 3 dose levels for repotrectinib: (1) 80 mg QD, (2) 160 mg QD and (3) 160 mg QD for 14 days followed by 160 mg BID; in combination with 80 mg QD of osimertinib~Part B: at the RP2D for all patients in combination with osimertinib.
Study NCT05393193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Point-of-Care Cepheid Xpert HIV-1
Description: Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
Study NCT05393193 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DTG/ABC/3TC
Description: Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
Study NCT05955508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Administration by intravenous (IV) infusion
Study NCT06177808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolverine cutting balloon
Description: As an intervention method for calcified coronary lesion modification, intervention group will undergo PCI after using the Wolverine cutting balloon for calcium modification.
Study NCT06242912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QOL - quality of life
Description: QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
Study NCT06242912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiographic or laboratory evaluation
Description: Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
Study NCT06335082 — intervention group
Intervention type: DEVICE
Intervention: Pulsed Field Ablation
Description: Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)
Study NCT05996198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Rift headset
Description: The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
Study NCT05996198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Device
Description: The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
Study NCT06119464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Education
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
Study NCT06119464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Audit and Feedback
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
Study NCT06119464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: Patient Engagement
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
Study NCT06119464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention: System Changes
Description: The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
Study NCT04831580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci
Description: Minimally invasive robotic-assisted radical or simple hysterectomy
Study NCT04831580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: open radical or simple hysterectomy
Study NCT06641310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endurance Exercise Therapy
Description: * Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study.
Study NCT05686395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Interscalene Block group
Description: ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
Study NCT05686395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
Description: Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
Study NCT05686395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.25%.
Study NCT04100135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actual device PFO closure
Description: Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
Study NCT04100135 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thienopyridine (clopidogrel or prasugrel)
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
Study NCT04100135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine (clopidogrel or prasugrel)
Description: Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure